Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria

BJU International

Volumn 110, Issue 6B, 2012, Pages

  Palisaar, Jüri R ^a   Noldus, Joachim ^a   Löppenberg, Björn ^a   Von Bodman, Christian ^a   Sommerer, Florian ^b   Eggert, Thilo ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

active surveillance; histopathological outcome; low risk; misclassification; prostate cancer; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; COHORT ANALYSIS; DISEASE SURVEILLANCE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ERROR; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEMINAL VESICLE DISEASE; SEMINAL VESICLE METASTASIS; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

AGED; DIAGNOSTIC ERRORS; HUMANS; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 84865516871     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10935.x     Document Type: Article

References (39)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
2. Schröder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
3. Hayes JH, Ollendorf DA, Pearson SD, et al,. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373-80
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
5. Bastian PJ, Mangold LA, Epstein JI, Partin AW,. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-5 (Pubitemid 39425375)
6. Dall'Era MA, Cooperberg MR, Chan JM, et al,. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 1650-9 (Pubitemid 351536825)
7. D'Amico AV, Coleman CN,. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol 1996; 14: 304-15
8. Patel MI, DeConcini DT, Lopez-Corona E, et al,. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520-4 (Pubitemid 38365409)
9. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M,. Active surveillance: a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008; 101: 165-9 (Pubitemid 350294039)
10. Van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH,. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 1560-3 (Pubitemid 350052404)
11. Van As NJ, Norman AR, Thomas K, et al,. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54: 1297-305
12. Klotz L,. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23: 8165-9 (Pubitemid 46211550)
13. Roemeling S, Roobol MJ, Postma R, et al,. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006; 50: 475-82 (Pubitemid 44189069)
14. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR,. Predictors of treatment after initial surveillance in men with PCa: results from CaPSURE. J Urol 2003; 170: 2279-83 (Pubitemid 37413975)
15. Hardie C, Parker C, Norman A, et al,. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956-60 (Pubitemid 40655686)
16. Choo R, Klotz L, Danjoux C, et al,. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-9 (Pubitemid 34240696)
17. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J,. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for PCa, Sweden section. Int J Clin Pract 2007; 120: 170-4
18. Al Otaibi M, Ross P, Fahmy N, et al,. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 2008; 113: 286-92
19. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD,. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-7
20. European Association of Urology. EAU guidelines. 2011. Available at: http://www.uroweb.org/guidelines/online-guidelines/. Accessed January 23, 2012
21. McNeal JE, Redwine EA, Freiha FS, Stamey TA,. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Pathol 1988; 12: 897-906 (Pubitemid 19011040)
22. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after RP, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
23. Carter HB, Sauvageot J, Walsh PC, Epstein JL,. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 1997; 157: 2206-9 (Pubitemid 27208672)
24. Stephenson AJ, Scardino PT, Eastham JA, et al,. Postoperative nomogram predicting the 10-year probability of PCa recurrence after radical prostatectomy. J Clin Oncol 2005; 25: 7005-12
25. Suardi N, Capitanio U, Chun FK, et al,. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113: 2068-72
26. Conti SL, Dallèra M, Fradet V, Cowan JE, Simko J, Carroll PR,. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 1628-33
27. Mufarrij P, Sankin A, Godoy G, Lepor H,. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology 2010; 76: 689-92
28. Ploussard G, Xylinas E, Salomon L, et al,. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009; 56: 891-8
29. Capitanio U, Karakiewicz PI, Valiquette L,. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009; 73: 1087-91
30. Numao N, Kawakami S, Yokoyama M, et al,. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensinal 26-core systematic biopsy. Eur Urol 2007; 52: 1663-8
31. Scattoni V, Raber M, Abdollah F, et al,. Biopsy schemes with the fewest cores for detecting 95% of the PCas detected by a 24-core biopsy. Eur Urol 2010; 57: 1-8
32. Lughezzani G, Sun M, Budäus L, et al,. Effect of the number of biopsy cores on prostate cancer detection and staging. Future Oncol 2010; 6: 381-90
33. Merrick GS, Gutman S, Andreini H, et al,. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 2007; 52: 715-23
34. Taymoorian K, Thomas A, Slowinski T, et al,. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. Anticancer Res 2007; 27: 4315-20
35. Mitterberger M, Horninger W, Pelzer A, et al,. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. Prostate 2007; 67: 1537-42 (Pubitemid 47536152)
36. Aigner F, Pallwein L, Junker D, et al,. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. J Urol 2010; 184: 913-7
37. Braeckman J, Autier P, Soviany C, et al,. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 2008; 102: 1560-5
38. Lawrentschuk N, Fleshner N,. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009; 103: 730-3
39. Kim CK, Park BK, Kim B,. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol 2010; 194: 1461-9